DCBWhatIsTheEvidence？药涂球囊临床研究进展..pptVIP

Downstream Safety Demonstrated at 1X and 4X Doses No infarcts or embolic-occlusive events observed No particulate observed No skeletal muscle necrosis observed Also true at 1 hour in vivo Bard/Lutonix is investing in rigorous clinical studies in PAD to expand and refine treatment options and indications. CLI patients face poor clinical outcomes with existing treatments and DCB is a viable option. Lutonix DCB provides an innovative, state of the art solution for treating BTK/CLI patients that delivers an optimal amount of drug to the diseased vessel while minimizing systemic and downstream